154 related articles for article (PubMed ID: 33661188)
41. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis.
Lin PC; Lin JK; Lin CC; Wang HS; Yang SH; Jiang JK; Lan YT; Lin TC; Li AF; Chen WS; Chang SC
Int J Colorectal Dis; 2012 Oct; 27(10):1333-8. PubMed ID: 22426691
[TBL] [Abstract][Full Text] [Related]
42. Serum Midkine is a clinical significant biomarker for colorectal cancer and associated with poor survival.
Kemper M; Hentschel W; Graß JK; Stüben BO; Konczalla L; Rawnaq T; Ghadban T; Izbicki JR; Reeh M
Cancer Med; 2020 Mar; 9(6):2010-2018. PubMed ID: 31984657
[TBL] [Abstract][Full Text] [Related]
43. TNM staging for GIT cancers is correlated with the level of MMPs and TGF-β1.
El-Ashmawy NE; Khedr NF; Mansour MG; Al-Ashmawy GM
Clin Exp Med; 2020 Nov; 20(4):545-555. PubMed ID: 32772210
[TBL] [Abstract][Full Text] [Related]
44. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
[TBL] [Abstract][Full Text] [Related]
45. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
Li Z; Zhu H; Pang X; Mao Y; Yi X; Li C; Lei M; Cheng X; Liang L; Wu J; Ding Y; Yang J; Sun Y; Zhang T; You D; Liu Z
BMC Cancer; 2022 Sep; 22(1):962. PubMed ID: 36076189
[TBL] [Abstract][Full Text] [Related]
46. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
47. Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis.
Sun L; Hu S; Yu L; Guo C; Sun L; Yang Z; Qi J; Ran Y
Int J Cancer; 2016 Jun; 138(11):2724-31. PubMed ID: 26756179
[TBL] [Abstract][Full Text] [Related]
48. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
[TBL] [Abstract][Full Text] [Related]
49. Clinical Value of Combined Determination of Serum B7-H4 with Carcinoembryonic Antigen, Osteopontin, or Tissue Polypeptide-Specific Antigen for the Diagnosis of Colorectal Cancer.
Wang P; Li C; Zhang F; Ma X; Gai X
Dis Markers; 2018; 2018():4310790. PubMed ID: 30363700
[TBL] [Abstract][Full Text] [Related]
50. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
Imaoka H; Toiyama Y; Fujikawa H; Hiro J; Saigusa S; Tanaka K; Inoue Y; Mohri Y; Mori T; Kato T; Toden S; Goel A; Kusunoki M
Ann Oncol; 2016 Oct; 27(10):1879-86. PubMed ID: 27502702
[TBL] [Abstract][Full Text] [Related]
51. Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer.
Vocka M; Langer D; Fryba V; Petrtyl J; Hanus T; Kalousova M; Zima T; Petruzelka L
Cancer Biomark; 2018; 21(4):869-874. PubMed ID: 29400662
[TBL] [Abstract][Full Text] [Related]
52. Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced colorectal neoplasia.
Gimeno-García AZ; Triñanes J; Quintero E; Salido E; Nicolás-Pérez D; Adrián-de-Ganzo Z; Alarcón-Fernández O; Abrante B; Romero R; Carrillo M; Ramos L; Alonso I; Ortega J; Jiménez A
Gastroenterol Hepatol; 2016; 39(7):433-41. PubMed ID: 26601990
[TBL] [Abstract][Full Text] [Related]
53. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of CA19-9 in the follow-up of colorectal cancer patients with elevated preoperative serum CA19-9.
Yang SH; Jiang JK; Chang SC; Juang CJ; Lin JK
Hepatogastroenterology; 2013; 60(125):1021-7. PubMed ID: 23321120
[TBL] [Abstract][Full Text] [Related]
55. Circulating miR-338-5p is a potential diagnostic biomarker in colorectal cancer.
Bilegsaikhan E; Liu HN; Shen XZ; Liu TT
J Dig Dis; 2018 Jul; 19(7):404-410. PubMed ID: 29952077
[TBL] [Abstract][Full Text] [Related]
56. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
57. Serum TEM5 and TEM7 concentrations correlate with clinicopathologic features and poor prognosis of colorectal cancer patients.
Pietrzyk Ł; Wdowiak P
Adv Med Sci; 2019 Sep; 64(2):402-408. PubMed ID: 31352222
[TBL] [Abstract][Full Text] [Related]
58. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer.
Takeda A; Otani Y; Iseki H; Takeuchi H; Aikawa K; Tabuchi S; Shinozuka N; Saeki T; Okazaki Y; Koyama I
World J Surg; 2007 Feb; 31(2):388-94. PubMed ID: 17219282
[TBL] [Abstract][Full Text] [Related]
59. The utility and prognostic value of CA 19-9 and CEA serum markers in the long-term follow up of patients with colorectal cancer. A single-center experience over 13 years.
Tumay V; Guner OS
Ann Ital Chir; 2020; 91():494-503. PubMed ID: 32990277
[TBL] [Abstract][Full Text] [Related]
60. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
